More and more people are talking about Novartis over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $112.13? Only time will tell. The information below will give you a ...

US FDA approves Novartis’ oral Fabhalta for treatment of adults with C3 glomerulopathy: Basel Saturday, March 22, 2025, 09:00 Hrs [IST] Novartis announced that oral Fabhalta (ip ...

Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the ...

Novartis announces positive data from phase III study of intrathecal onasemnogene abeparvovec in broad patient population with SMA: Basel Friday, March 21, 2025, 11:00 Hrs [IST] N ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Novartis Pharma Maroc has appointed Yahya Abdallah as country president for its Morocco, Tunisia, and Algeria (MTA) regional ...

An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.

Eurovision winner Charlie McGettigan and music therapist Professor Hilary Moss will lead the judging panel on an initiative designed to spotlight patient choirs and celebrate music’s therapeutic power ...

It’s not just American companies rethinking their diversity, equity, and inclusion (DEI) initiatives. Swiss pharma giants ...

Swiss pharmaceutical giants Roche and Novartis are revising their diversity policies in response to recent U.S. executive ...